Edwards Lifesciences Corporation (Edwards Lifesciences) and DexCom, Inc. (DexCom), announced the receipt of CE Mark for an automatic glucose monitoring system. Edwards and DexCom co-developed this new system, which is indicated for automatic, real-time monitoring and trending of blood glucose concentration in critically ill adults in the hospital environment.
This CE Mark allows for commercialization of the system in the EU and the countries in Asia and Latin America that recognize the CE Mark. Market evaluations of a first generation product are expected to begin in a limited number of European sites before the end of the year.
The company claims that this glucose monitoring system will perform multiple automatic readings per hour that may provide a new level of trending insight designed to enable clinicians to effectively implement glycemic control.
Edwards Lifesciences provides products and technologies used for the treatment of patients suffering from advanced cardiovascular disease.
DexCom is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use.